Login
$RNTX
$0.38 -$0.02 (5.35%) After hours

$RNTX 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Other Events

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

04 Sep 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 Harnessing fibrosis, unleashing life Science Deck| September 2026 Copyright © 2026 Rein Therapeutics

27 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On August 21, 2026, Rein Therapeutics, Inc. (“Company”) received a notice of delisting (the “Notice”) from the Nasdaq Stock Market, LLC. The Notice stated that the Company had fallen below compliance with respect to the continued listing...

21 Jul 2026 8-K: Submission of Matters to a Vote of Security Holders

On July 20, 2026, Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, for the purposes of:

04 May 2026 8-K: Entry into a Material Definitive Agreement; Other Events

As Representative of the several Underwriters named on Schedule 1 attached hereto

02 Mar 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February ____, 2026, by and between Rein Therapeutics, Inc., a Delaware corporation (the “Company”), and _____________________, including its successors and assigns (“P...

19 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

16 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 15, 2026, by and between Rein Therapeutics, Inc., a Delaware corporation (the “Company”), and Funicular Funds, LP, including its successors and assigns (“Purcha...

11 Dec 2025 8-K: Termination of a Material Definitive Agreement

On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Sta...

03 Nov 2025 8-K: Other Events

FDA lifts clinical hold following review of Company’s Complete Response submission.

24 Oct 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

As previously disclosed by Rein Therapeutics, Inc. (the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with...

09 Oct 2025 8-K: Other Events

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial

22 Sep 2025 8-K: Other Events

On September 16, 2025, Rein Therapeutics, Inc. (the “Company”) received additional communication through preliminary meeting comments from the United States Food and Drug Administration (“FDA”) regarding the Clinical Hold Letter received...

09 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

As previously disclosed by Rein Therapeutics, Inc. (the “Company”, “we”, “us”) in a Current Report on Form 8-K filed on July 30, 2025, on July 29, 2025 (the “Effective Date”), we entered into a Pre-Paid Advance Agreement (the “PPA”) with...

19 Aug 2025 8-K: Other Events

AUSTIN, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) — Rein Therapeutics (“Rein”) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary ...

30 Jul 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS PREPAID ADVANCE AGREEMENT (this “Agreement”) dated as of July 29, 2025 is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and REIN THERAPEUTICS, INC., a Delaware corporation (the “Compan...

23 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

On July 23, 2025, Rein Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders, which was previously adjourned on June 24, 2025, to consider and vote upon the matters listed below. The following is a summary of th...

11 Jul 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

The Board of Directors of Rein Therapeutics, Inc., a Delaware corporation (the “Corporation”), having resolved to amend the Amended and Restated By-laws of the Corporation (the “By-laws”) as set forth below, the By-laws are hereby amende...

24 Jun 2025 8-K: Other Events

On June 24, 2025, Rein Therapeutics, Inc. (the “Company”) announced that it adjourned the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on Tuesday, June 24, 2025, until Wednesday, July 23, ...

12 Jun 2025 8-K: Other Events

On June 10, 2025, Rein Therapeutics, Inc. paused enrollment and patient dosing at its clinical trial sites in the United States (U.S.) for its Phase 2 RENEW trial of LTI-03. Rein is working with the U.S. Food and Drug Administration (FDA...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support